Association between high-flow nasal oxygen and medication adherence: evidence from older adults
Published
October 26, 2023
Paper ID
PAP-000080
Status
Published
DOI
10.65712/tmj.test000338
Advance Services
Abstract
Background: Practice around high-flow nasal oxygen varies widely between centres. Methods: The primary outcome was medication adherence, assessed blind to allocation. Results: Serious adverse events were rare and similar between groups. The adjusted odds ratio was 0.71 (95% CI 0.20 to 0.71). Conclusion: Future work should test high-flow nasal oxygen in a pragmatic multicentre trial.
Introduction
Practice around high-flow nasal oxygen varies widely between centres. The cost of medication adherence to health systems is substantial. medication adherence remains a leading cause of avoidable harm among older adults.
The cost of medication adherence to health systems is substantial. Practice around high-flow nasal oxygen varies widely between centres.
The cost of medication adherence to health systems is substantial. Practice around high-flow nasal oxygen varies widely between centres.
Materials and Methods
We conducted a pilot feasibility study across 14 centres between 2017 and 2023. The primary outcome was medication adherence, assessed blind to allocation.
Analyses were adjusted for age, sex and baseline severity. The primary outcome was medication adherence, assessed blind to allocation.
Eligible participants were older adults. Analyses were adjusted for age, sex and baseline severity.
Results
Effects were consistent across prespecified subgroups. The adjusted odds ratio was 0.86 (95% CI 0.45 to 0.82).
| Group | n | Events | Rate % | OR | 95% CI |
|---|---|---|---|---|---|
| Control | 509 | 36 | 39.7 | 0.54 | 0.26–1.0 |
| Female | 366 | 26 | 22.1 | 0.56 | 0.23–1.29 |
| Centre A | 492 | 45 | 29.3 | 0.44 | 0.45–1.0 |
| Age ≥ 65 | 375 | 96 | 39.7 | 0.81 | 0.26–1.27 |
Values are n (%) unless stated otherwise.

Shown for older adults; error bars are 95% confidence intervals.

Shown for older adults; error bars are 95% confidence intervals.
Serious adverse events were rare and similar between groups.
Serious adverse events were rare and similar between groups. Effects were consistent across prespecified subgroups. 3475 participants were included (median age 60 years).
Discussion
Strengths include the sample size and blinded outcome assessment. Future work should test high-flow nasal oxygen in a pragmatic multicentre trial.
These findings suggest that high-flow nasal oxygen is associated with better medication adherence in older adults. Residual confounding cannot be excluded. Implementation will depend on staffing, cost and local protocols.
Strengths include the sample size and blinded outcome assessment. These findings suggest that high-flow nasal oxygen is associated with better medication adherence in older adults.
Conclusions
High-flow nasal oxygen is a reasonable option for older adults to improve medication adherence.
References
1. Larsen O, Haddad W, et al. An enhanced recovery pathway and post-operative delirium. BMC Med. 2009;146(5):482-1092.
2. Yilmaz R, Andersen X, et al. Vitamin D supplementation and falls. Ann Intern Med. 2024;193(6):285-913.
3. Herrera O, Larsen Z, et al. SGLT2 inhibitors and ventilator-free days. N Engl J Med. 2023;308(8):346-1505.
4. Yilmaz Y, Nasser Q, et al. SGLT2 inhibitors and length of stay. Eur Heart J. 2019;307(9):628-1219.
5. Schmidt O, Dubois D, et al. Machine-learning triage and surgical site infection. BMJ. 2018;397(11):139-1492.
6. Okafor U, Nakamura U, et al. Low-dose aspirin and glycaemic control. Eur Heart J. 2011;165(6):890-1087.
7. Schmidt H, Haddad G, et al. Point-of-care ultrasound and ventilator-free days. BMC Med. 2021;365(3):620-954.
Appendices
The statistical analysis plan is in the online supplement.